|
WO2021054449A1
|
|
Lbm, cpc, opc, production and quality control methods therefor, kit, graft material, and disease model
|
|
WO2021039824A1
|
|
Rna methyltransferase inhibitor, screening method therefor, anti-cancer agent efficacy assessment marker, and kit for effectively predicting ftsj1 inhibitor
|
|
WO2020203855A1
|
|
Implant material containing surface-treated aromatic polyether ketone and manufacturing method therefor
|
|
WO2020149105A1
|
|
Method and kit for determining possibility of onset of iga nephropathy
|
|
WO2020067570A1
|
|
Wet spun fibers, wet formed film, and production method therefor
|
|
WO2020003978A1
|
|
Agent for enhancing phagocytosis ability of neutrophils
|
|
WO2019230558A1
|
|
Novel monoclonal antibody having anti-inflammatory action
|
|
EP3808362A1
|
|
Reactive oxygen production inhibitor and/or scavenging promoter
|
|
WO2019216313A1
|
|
Medication useful for cardiovascular diseases
|
|
EP3791894A1
|
|
Anti-s100a8/a9 antibody and use thereof
|
|
WO2019189827A1
|
|
Nucleic acid construct, medicinal composition, anticancer agent, antiviral agent and antibacterial agent
|
|
WO2019176864A1
|
|
Agent for treatment or prevention of muscular-dystrophy-related cardiomyopathy
|
|
WO2019160129A1
|
|
Cancer lesion tissue evaluation for optimizing effect of boron neutron capture therapy
|
|
US2019201555A1
|
|
Method of evaluating lymphatic system function
|
|
WO2019124423A1
|
|
Agent for progression suppression, treatment, prophylaxis and/or recurrence prevention of cancer
|
|
WO2019026347A1
|
|
Thermotherapy device
|
|
WO2018207498A1
|
|
Puncture robot and puncture control program
|
|
WO2018211833A1
|
|
Magnetic field measuring device
|
|
WO2019073623A1
|
|
Optical-fiber-type measurement device and optical-fiber-type measurement method
|
|
WO2019077778A1
|
|
Eddy-current flaw testing method and eddy-current flaw testing device
|
